Leukemia
Conditions
Keywords
adult acute myeloid leukemia with t(15;17)(q22;q12), adult acute promyelocytic leukemia (M3), childhood acute promyelocytic leukemia (M3), adult acute myeloid leukemia in remission, untreated adult acute myeloid leukemia, childhood acute myeloid leukemia in remission, untreated childhood acute myeloid leukemia and other myeloid malignancies
Brief summary
RATIONALE: Studying samples fo tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. PURPOSE: This research study is studying biomarkers in tissue samples from patients with acute promyelocytic leukemia.
Detailed description
OBJECTIVES: * Demonstrate that S100A10 is expressed on APL cells and that levels of S100A10 correspond to the amount of fibrinolytic activity. * Evaluate the impact of ATRA on S100A10 level and fibrinolytic activity in vitro. * Evaluate the impact of S100A10 knockdown on fibrinolytic activity. * Correlate in vitro findings in cell culture to primary patient samples both pre- and post-ATRA therapy. OUTLINE: This is a multicenter study. Previously collected samples are analyzed via flow cytometry and western blot analysis. Cell surface levels of S100A10 and annexin A2 are correlated to the promyelocyte population and total protein levels are examined to determine total annexin A2 and S100A10 in acute promyelocytic leukemia cells.
Interventions
GENETICprotein expression analysis
GENETICwestern blotting
OTHERflow cytometry
OTHERlaboratory biomarker analysis
Sponsors
National Cancer Institute (NCI)
Children's Oncology Group
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 120 Years
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Diagnosis of acute promyelocytic leukemia * Available cryopreserved cells from diagnosis or cryopreserved cells from remission (germline) PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Demonstration that S100A10 is expressed on acute promyelocytic leukemia cells and that levels of S100A10 correspond to the amount of fibrinolytic activity | — |
| Evaluation of the impact of all-trans retinoic acid (ATRA) on S100A10 level and fibrinolytic activity in vitro | — |
| Evaluation of the impact of S100A10 knockdown on fibrinolytic activity | — |
| Correlation of in vitro findings in cell culture to primary patient samples both pre- and post-ATRA therapy | — |
Outcome results
None listed